Details of the Drug

General Information of Drug (ID: DM6I5GR)

• Drug Name: Promethazine
• Synonyms: Antiallersin; Aprobit; Avomine; Camergan; Dimapp; Diphergan; Diprazin; Diprazine; Diprozin; Fargan; Fenazil; Fenetazina; Fenetazine; Genphen; Hiberna; Histargan; Iergigan; Isophenergan; Isopromethazine; Lercigan; Lergigan; Metaryl; Pelpica; Phargan; Phenargan; Phenerzine; Phensedyl; Pilothia; Pilpophen; Pipolphene; Proazaimine; Proazamine; Procit; Promacot; Promazinamide; Promergan; Promesan; Prometasin; Prometazin; Prometazina; Prometazine; Prometh; Promethacon; Promethaine; Promethazin; PromethazineHcl; Promethazinum; Promethegan; Promethiazine; Promezathine; Prorex; Protazine; Prothazin; Prothazine; Provigan; Pyrethia; Pyrethiazine; Remsed; Romergan; Rumergan; Tanidil; Thiergan; Valergine; Vallergine; Lilly 01516; Lilly 1516; RP 3277; SKF 1498; WY 509; A-91033; Atosil (TN); Avomine (TN); Fargan (TN); Farganesse (TN); Lergigan (TN); Phenergan (TN); Phenoject-50; Pro-50; Prometazina [INN-Spanish]; Promethazine [INN:BAN]; Promethazinum [INN-Latin]; Promethegan (TN); Prothiazine (TN); Receptozine (TN); Romergan (TN); Zipan-25; Dimethylamino-isopropyl-phenthiazin; Dimethylamino-isopropyl-phenthiazin [German]; Promethazine (JAN/INN)

Indication

Disease Entry	ICD 11	Status	REF
Hyperemesis gravidarum	N.A.	Approved	[1]
Nausea	MD90	Approved	[2]
Seasonal allergic rhinitis	CA08.01	Approved	[1]
Urticaria	EB00-EB05	Approved	[1]
Vasomotor/allergic rhinitis	CA08	Approved	[1]
Vomiting	MD90	Approved	[1]
Middle East Respiratory Syndrome (MERS)	1D64	Investigative	[3]
Severe acute respiratory syndrome (SARS)	1D65	Investigative	[4]

• Therapeutic Class: Antiallergic Agents
• Affected Organisms: Humans and other mammals
• ATC Code:
  D04AA10: Promethazine
  D04AA: Antihistamines for topical use
  D04A: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.
  D04: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.
  D: DERMATOLOGICALS
  R06AD02: Promethazine
  R06AD: Phenothiazine derivatives
  R06A: ANTIHISTAMINES FOR SYSTEMIC USE
  R06: ANTIHISTAMINES FOR SYSTEMIC USE
  R: RESPIRATORY SYSTEM
  R06AD02: Promethazine
  R06AD: Phenothiazine derivatives
  R06A: ANTIHISTAMINES FOR SYSTEMIC USE
  R06: ANTIHISTAMINES FOR SYSTEMIC USE
  R: RESPIRATORY SYSTEM
  R06AD02: Promethazine
  R06AD: Phenothiazine derivatives
  R06A: ANTIHISTAMINES FOR SYSTEMIC USE
  R06: ANTIHISTAMINES FOR SYSTEMIC USE
  R: RESPIRATORY SYSTEM
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 284.4
  Logarithm of the Partition Coefficient (xlogp); 4.8
  Rotatable Bond Count (rotbonds); 3
  Hydrogen Bond Donor Count (hbonddonor); 0
  Hydrogen Bond Acceptor Count (hbondacc); 3
• ADMET Property:
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [5]
  Clearance: The drug present in the plasma can be removed from the body at the rate of 14 mL/min/kg [6]
  Elimination: 2% of drug is excreted from urine in the unchanged form [5]
  Half-life: The concentration or amount of drug in body reduced by one-half in 14 hours [6]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 5.03281 micromolar/kg/day [7]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.09% [6]
  Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 14 L/kg [6]
• Chemical Identifiers:
  Formula: C17H20N2S
  IUPAC Name: N,N-dimethyl-1-phenothiazin-10-ylpropan-2-amine
  Canonical SMILES: CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C
  InChI: InChI=1S/C17H20N2S/c1-13(18(2)3)12-19-14-8-4-6-10-16(14)20-17-11-7-5-9-15(17)19/h4-11,13H,12H2,1-3H3
  InChIKey: PWWVAXIEGOYWEE-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 4927
  ChEBI ID: CHEBI:8461
  CAS Number: 60-87-7
  UNII: FF28EJQ494
  DrugBank ID: DB01069
  TTD ID: D0T2XU
  VARIDT ID: DR00674
  INTEDE ID: DR1353
  ACDINA ID: D00561
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Histamine H1 receptor (H1R)	TTTIBOJ	HRH1_HUMAN	Antagonist	[8]
HUMAN clathrin-mediated endocytosis (RME)	TTAIY2U	.	Inhibitor	[4]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[9]
Cytochrome P450 2B6 (CYP2B6)	DEPKLMQ	CP2B6_HUMAN	Substrate	[10]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Activating molecule in BECN1-regulated autophagy protein 1 (AMBRA1)	OTY0YGT9	AMRA1_HUMAN	Gene/Protein Processing	[11]
Apoptosis regulator Bcl-2 (BCL2)	OT9DVHC0	BCL2_HUMAN	Gene/Protein Processing	[11]
Autophagy protein 5 (ATG5)	OT4T5SMS	ATG5_HUMAN	Gene/Protein Processing	[11]
Bcl-2 homologous antagonist/killer (BAK1)	OTDP6ILW	BAK_HUMAN	Gene/Protein Processing	[11]
Bcl-2-like protein 1 (BCL2L1)	OTRC5K9O	B2CL1_HUMAN	Gene/Protein Processing	[11]
Cholinesterase (BCHE)	OTOH3WQ9	CHLE_HUMAN	Gene/Protein Processing	[12]
Heat shock factor protein 1 (HSF1)	OTYNJ4KP	HSF1_HUMAN	Gene/Protein Processing	[13]
Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)	OT2YYI1A	MCL1_HUMAN	Gene/Protein Processing	[11]
Interleukin-1 alpha (IL1A)	OTPSGILV	IL1A_HUMAN	Gene/Protein Processing	[14]
Natural cytotoxicity triggering receptor 3 ligand 1 (NCR3LG1)	OT15YWU7	NR3L1_HUMAN	Gene/Protein Processing	[15]

Molecular Expression Atlas of This Drug

• The Studied Disease: Hyperemesis gravidarum

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Histamine H1 receptor (H1R)	DTT	HRH1	6.74E-01	0.13	0.43
Cytochrome P450 2B6 (CYP2B6)	DME	CYP2B6	4.32E-01	4.39E-02	4.30E-01
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	8.70E-01	2.98E-02	1.22E-01

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Promethazine

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Rolapitant	DM8XP26	Moderate	Decreased metabolism of Promethazine caused by Rolapitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[16]
Cyclizine	DM9G7BS	Moderate	Additive anticholinergic effects by the combination of Promethazine and Cyclizine.	Nausea/vomiting [MD90]	[17]
Metoclopramide	DMFA5MY	Major	Additive antidopaminergic effects by the combination of Promethazine and Metoclopramide.	Nausea/vomiting [MD90]	[18]

Coadministration of a Drug Treating the Disease Different from Promethazine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Promethazine and Ivosidenib.	Acute myeloid leukaemia [2A60]	[19]
Midostaurin	DMI6E0R	Moderate	Increased risk of prolong QT interval by the combination of Promethazine and Midostaurin.	Acute myeloid leukaemia [2A60]	[20]
Idarubicin	DMM0XGL	Moderate	Increased risk of prolong QT interval by the combination of Promethazine and Idarubicin.	Acute myeloid leukaemia [2A60]	[20]
Arn-509	DMT81LZ	Moderate	Increased risk of prolong QT interval by the combination of Promethazine and Arn-509.	Acute myeloid leukaemia [2A60]	[21]
Gilteritinib	DMTI0ZO	Moderate	Increased risk of prolong QT interval by the combination of Promethazine and Gilteritinib.	Acute myeloid leukaemia [2A60]	[22]
Oliceridine	DM6MDCF	Moderate	Increased risk of prolong QT interval by the combination of Promethazine and Oliceridine.	Acute pain [MG31]	[20]
Mepyramine	DMB4SFH	Moderate	Additive anticholinergic effects by the combination of Promethazine and Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[23]
Trimethaphan	DMHF4IQ	Moderate	Additive hypotensive effects by the combination of Promethazine and Trimethaphan.	Aneurysm/dissection [BD50]	[24]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Promethazine and Ivabradine.	Angina pectoris [BA40]	[21]
Bepridil	DM0RKS4	Major	Increased risk of prolong QT interval by the combination of Promethazine and Bepridil.	Angina pectoris [BA40]	[20]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Promethazine and Dronedarone.	Angina pectoris [BA40]	[20]
Nifedipine	DMSVOZT	Moderate	Additive hypotensive effects by the combination of Promethazine and Nifedipine.	Angina pectoris [BA40]	[25]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Promethazine and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[26]
Cilostazol	DMZMSCT	Moderate	Increased risk of prolong QT interval by the combination of Promethazine and Cilostazol.	Arterial occlusive disease [BD40]	[20]
Posaconazole	DMUL5EW	Moderate	Increased risk of prolong QT interval by the combination of Promethazine and Posaconazole.	Aspergillosis [1F20]	[20]
Levalbuterol	DM5YBO1	Moderate	Increased risk of ventricular arrhythmias by the combination of Promethazine and Levalbuterol.	Asthma [CA23]	[27]
Pirbuterol	DMI5678	Moderate	Increased risk of prolong QT interval by the combination of Promethazine and Pirbuterol.	Asthma [CA23]	[28]
Ephedrine	DMMV0KW	Moderate	Antagonize the effect of Promethazine when combined with Ephedrine.	Asthma [CA23]	[29]
Lisdexamfetamine	DM6W8V5	Moderate	Antagonize the effect of Promethazine when combined with Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[29]
Desipramine	DMT2FDC	Moderate	Increased plasma concentrations of Promethazine and Desipramine due to competitive inhibition of the same metabolic pathway.	Attention deficit hyperactivity disorder [6A05]	[30]
Ofloxacin	DM0VQN3	Moderate	Increased risk of prolong QT interval by the combination of Promethazine and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[31]
Clarithromycin	DM4M1SG	Moderate	Increased risk of prolong QT interval by the combination of Promethazine and Clarithromycin.	Bacterial infection [1A00-1C4Z]	[20]
Sparfloxacin	DMB4HCT	Major	Increased risk of prolong QT interval by the combination of Promethazine and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[31]
Gemifloxacin	DMHT34O	Moderate	Increased risk of prolong QT interval by the combination of Promethazine and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[31]
Levofloxacin	DMS60RB	Moderate	Increased risk of prolong QT interval by the combination of Promethazine and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[31]
Retigabine	DMGNYIH	Moderate	Increased risk of prolong QT interval by the combination of Promethazine and Retigabine.	Behcet disease [4A62]	[20]
Cariprazine	DMJYDVK	Moderate	Additive anticholinergic effects by the combination of Promethazine and Cariprazine.	Bipolar disorder [6A60]	[17]
Eribulin	DM1DX4Q	Moderate	Increased risk of prolong QT interval by the combination of Promethazine and Eribulin.	Breast cancer [2C60-2C6Y]	[20]
Lapatinib	DM3BH1Y	Moderate	Increased risk of prolong QT interval by the combination of Promethazine and Lapatinib.	Breast cancer [2C60-2C6Y]	[20]
Acetylcholine	DMDF79Z	Moderate	Antagonize the effect of Promethazine when combined with Acetylcholine.	Cataract [9B10]	[32]
PF-04449913	DMSB068	Moderate	Increased risk of prolong QT interval by the combination of Promethazine and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[33]
Umeclidinium	DM4E8O9	Moderate	Additive anticholinergic effects by the combination of Promethazine and Umeclidinium.	Chronic obstructive pulmonary disease [CA22]	[34]
Olodaterol	DM62B78	Moderate	Increased risk of ventricular arrhythmias by the combination of Promethazine and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[28]
Vilanterol	DMF5EK1	Moderate	Increased risk of prolong QT interval by the combination of Promethazine and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[27]
Tiotropium	DMFDC0Q	Moderate	Additive anticholinergic effects by the combination of Promethazine and Tiotropium.	Chronic obstructive pulmonary disease [CA22]	[34]
Revefenacin	DMMP5SI	Moderate	Additive anticholinergic effects by the combination of Promethazine and Revefenacin.	Chronic obstructive pulmonary disease [CA22]	[34]
Indacaterol	DMQJHR7	Moderate	Increased risk of ventricular arrhythmias by the combination of Promethazine and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[28]
Arformoterol	DMYM974	Moderate	Increased risk of ventricular arrhythmias by the combination of Promethazine and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[28]
Halothane	DM80OZ5	Moderate	Increased risk of prolong QT interval by the combination of Promethazine and Halothane.	Corneal disease [9A76-9A78]	[20]
Sevoflurane	DMC9O43	Moderate	Increased risk of prolong QT interval by the combination of Promethazine and Sevoflurane.	Corneal disease [9A76-9A78]	[20]
Probucol	DMVZQ2M	Moderate	Increased risk of prolong QT interval by the combination of Promethazine and Probucol.	Coronary atherosclerosis [BA80]	[20]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Promethazine and Pasireotide.	Cushing syndrome [5A70]	[20]
Osilodrostat	DMIJC9X	Moderate	Increased risk of prolong QT interval by the combination of Promethazine and Osilodrostat.	Cushing syndrome [5A70]	[21]
Cyclandelate	DMO0R76	Moderate	Additive hypotensive effects by the combination of Promethazine and Cyclandelate.	Dementia [6D80-6D8Z]	[25]
Isocarboxazid	DMAF1NB	Moderate	Additive hypotensive effects by the combination of Promethazine and Isocarboxazid.	Depression [6A70-6A7Z]	[35]
Escitalopram	DMFK9HG	Major	Increased risk of prolong QT interval by the combination of Promethazine and Escitalopram.	Depression [6A70-6A7Z]	[36]
OPC-34712	DMHG57U	Moderate	Additive anticholinergic effects by the combination of Promethazine and OPC-34712.	Depression [6A70-6A7Z]	[17]
Clomipramine	DMINRKW	Moderate	Increased plasma concentrations of Promethazine and Clomipramine due to competitive inhibition of the same metabolic pathway.	Depression [6A70-6A7Z]	[30]
Doxepin	DMPI98T	Moderate	Increased plasma concentrations of Promethazine and Doxepin due to competitive inhibition of the same metabolic pathway.	Depression [6A70-6A7Z]	[30]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Promethazine and Esketamine.	Depression [6A70-6A7Z]	[37]
Mepenzolate	DM8YU2F	Moderate	Additive anticholinergic effects by the combination of Promethazine and Mepenzolate.	Digestive system disease [DE2Z]	[17]
Tetrabenazine	DMYWQ0O	Major	Additive antidopaminergic effects by the combination of Promethazine and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[38]
Deutetrabenazine	DMUPFLI	Major	Increased risk of prolong QT interval by the combination of Promethazine and Deutetrabenazine.	Dystonic disorder [8A02]	[39]
Ingrezza	DMVPLNC	Moderate	Additive CNS depression effects by the combination of Promethazine and Ingrezza.	Dystonic disorder [8A02]	[40]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Promethazine caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[41]
Diphenhydramine	DMKQTBA	Moderate	Additive anticholinergic effects by the combination of Promethazine and Diphenhydramine.	Episodic vestibular syndrome [AB31]	[17]
Nadolol	DMW6GVL	Moderate	Additive hypotensive effects by the combination of Promethazine and Nadolol.	Essential hypertension [BA00]	[25]
Solifenacin	DMG592Q	Moderate	Additive anticholinergic effects by the combination of Promethazine and Solifenacin.	Functional bladder disorder [GC50]	[17]
Mirabegron	DMS1GYT	Moderate	Decreased metabolism of Promethazine caused by Mirabegron mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[42]
Sunitinib	DMCBJSR	Moderate	Increased risk of prolong QT interval by the combination of Promethazine and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[20]
Pilocarpine	DMV9ADG	Moderate	Antagonize the effect of Promethazine when combined with Pilocarpine.	Glaucoma [9C61]	[32]
Carvedilol	DMHTEAO	Moderate	Additive hypotensive effects by the combination of Promethazine and Carvedilol.	Heart failure [BD10-BD1Z]	[25]
Procarbazine	DMIK367	Moderate	Additive CNS depression effects by the combination of Promethazine and Procarbazine.	Hodgkin lymphoma [2B30]	[35]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Promethazine caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[43]
Saquinavir	DMG814N	Major	Increased risk of prolong QT interval by the combination of Promethazine and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[44]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of prolong QT interval by the combination of Promethazine and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Acebutolol	DM0TI4U	Moderate	Additive hypotensive effects by the combination of Promethazine and Acebutolol.	Hypertension [BA00-BA04]	[25]
Captopril	DM458UM	Moderate	Additive hypotensive effects by the combination of Promethazine and Captopril.	Hypertension [BA00-BA04]	[25]
Penbutolol	DM4ES8F	Moderate	Additive hypotensive effects by the combination of Promethazine and Penbutolol.	Hypertension [BA00-BA04]	[25]
Nebivolol	DM7F1PA	Moderate	Additive hypotensive effects by the combination of Promethazine and Nebivolol.	Hypertension [BA00-BA04]	[25]
Levamlodipine	DM92S6N	Moderate	Additive hypotensive effects by the combination of Promethazine and Levamlodipine.	Hypertension [BA00-BA04]	[25]
TAK-491	DMCF6SX	Moderate	Additive hypotensive effects by the combination of Promethazine and TAK-491.	Hypertension [BA00-BA04]	[25]
Diazoxide	DML1538	Moderate	Additive hypotensive effects by the combination of Promethazine and Diazoxide.	Hypertension [BA00-BA04]	[25]
Deserpidine	DMRH7CV	Moderate	Additive hypotensive effects by the combination of Promethazine and Deserpidine.	Hypertension [BA00-BA04]	[25]
Hydralazine	DMU8JGH	Moderate	Additive hypotensive effects by the combination of Promethazine and Hydralazine.	Hypertension [BA00-BA04]	[25]
Clevidipine butyrate	DMW4M97	Moderate	Additive hypotensive effects by the combination of Promethazine and Clevidipine butyrate.	Hypertension [BA00-BA04]	[25]
Givosiran	DM5PFIJ	Moderate	Decreased metabolism of Promethazine caused by Givosiran mediated inhibition of CYP450 enzyme.	Inborn porphyrin/heme metabolism error [5C58]	[45]
Belladonna	DM2RBWK	Moderate	Additive anticholinergic effects by the combination of Promethazine and Belladonna.	Infectious gastroenteritis/colitis [1A40]	[17]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Promethazine caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[46]
ITI-007	DMUQ1DO	Moderate	Additive anticholinergic effects by the combination of Promethazine and ITI-007.	Insomnia [7A00-7A0Z]	[17]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of lowers seizure threshold by the combination of Promethazine and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[20]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Decreased metabolism of Promethazine caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[21]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Promethazine and Crizotinib.	Lung cancer [2C25]	[47]
Dacomitinib	DMOH8VY	Moderate	Decreased metabolism of Promethazine caused by Dacomitinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[48]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Promethazine and Osimertinib.	Lung cancer [2C25]	[49]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Promethazine and Lumefantrine.	Malaria [1F40-1F45]	[37]
Halofantrine	DMOMK1V	Major	Increased risk of prolong QT interval by the combination of Promethazine and Halofantrine.	Malaria [1F40-1F45]	[50]
Hydroxychloroquine	DMSIVND	Major	Increased risk of prolong QT interval by the combination of Promethazine and Hydroxychloroquine.	Malaria [1F40-1F45]	[51]
Primaquine	DMWQ16I	Moderate	Increased risk of prolong QT interval by the combination of Promethazine and Primaquine.	Malaria [1F40-1F45]	[20]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of prolong QT interval by the combination of Promethazine and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[21]
Arsenic trioxide	DM61TA4	Major	Increased risk of ventricular arrhythmias by the combination of Promethazine and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[52]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Promethazine and Vemurafenib.	Melanoma [2C30]	[20]
LGX818	DMNQXV8	Moderate	Increased risk of prolong QT interval by the combination of Promethazine and LGX818.	Melanoma [2C30]	[53]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Promethazine and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[54]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Promethazine and Lasmiditan.	Migraine [8A80]	[55]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Promethazine and Flibanserin.	Mood disorder [6A60-6E23]	[56]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Promethazine and Panobinostat.	Multiple myeloma [2A83]	[57]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Promethazine and Siponimod.	Multiple sclerosis [8A40]	[37]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Promethazine and Fingolimod.	Multiple sclerosis [8A40]	[20]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Promethazine and Ozanimod.	Multiple sclerosis [8A40]	[58]
Romidepsin	DMT5GNL	Moderate	Increased risk of prolong QT interval by the combination of Promethazine and Romidepsin.	Mycosis fungoides [2B01]	[20]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Promethazine caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[21]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Promethazine and Nilotinib.	Myeloproliferative neoplasm [2A20]	[20]
Dasatinib	DMJV2EK	Moderate	Increased risk of prolong QT interval by the combination of Promethazine and Dasatinib.	Myeloproliferative neoplasm [2A20]	[59]
Dextroamphetamine	DMMIHVP	Moderate	Antagonize the effect of Promethazine when combined with Dextroamphetamine.	Narcolepsy [7A20]	[29]
Phenindamine	DMDTC7R	Moderate	Additive anticholinergic effects by the combination of Promethazine and Phenindamine.	Nasopharyngitis [CA00]	[17]
Bupropion	DM5PCS7	Major	Increased risk of lowers seizure threshold by the combination of Promethazine and Bupropion.	Nicotine use disorder [6C4A]	[20]
Entrectinib	DMMPTLH	Moderate	Increased risk of prolong QT interval by the combination of Promethazine and Entrectinib.	Non-small cell lung cancer [2C25]	[37]
Phendimetrazine	DM6TS1N	Moderate	Antagonize the effect of Promethazine when combined with Phendimetrazine.	Obesity [5B80-5B81]	[29]
Lorcaserin	DMG6OYJ	Moderate	Decreased metabolism of Promethazine caused by Lorcaserin mediated inhibition of CYP450 enzyme.	Obesity [5B80-5B81]	[60]
Polythiazide	DMCH80F	Moderate	Additive hypotensive effects by the combination of Promethazine and Polythiazide.	Oedema [MG29]	[25]
Levomethadyl Acetate	DM06HG5	Major	Increased risk of prolong QT interval by the combination of Promethazine and Levomethadyl Acetate.	Opioid use disorder [6C43]	[21]
Lofexidine	DM1WXA6	Moderate	Additive hypotensive effects by the combination of Promethazine and Lofexidine.	Opioid use disorder [6C43]	[20]
Rucaparib	DM9PVX8	Moderate	Increased risk of prolong QT interval by the combination of Promethazine and Rucaparib.	Ovarian cancer [2C73]	[20]
Flavoxate	DMKV4NL	Moderate	Additive anticholinergic effects by the combination of Promethazine and Flavoxate.	Pain [MG30-MG3Z]	[17]
Methamphetamine	DMPM4SK	Moderate	Antagonize the effect of Promethazine when combined with Methamphetamine.	Pain [MG30-MG3Z]	[61]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Promethazine and Triclabendazole.	Parasitic worm infestation [1F90]	[20]
Safinamide	DM0YWJC	Moderate	Additive hypotensive effects by the combination of Promethazine and Safinamide.	Parkinsonism [8A00]	[35]
Pergolide	DM14MAE	Moderate	Antagonize the effect of Promethazine when combined with Pergolide.	Parkinsonism [8A00]	[62]
Opicapone	DM1BKA6	Moderate	Antagonize the effect of Promethazine when combined with Opicapone.	Parkinsonism [8A00]	[62]
Rasagiline	DM3WKQ4	Moderate	Additive CNS depression effects by the combination of Promethazine and Rasagiline.	Parkinsonism [8A00]	[35]
Levodopa	DMN3E57	Moderate	Additive hypotensive effects by the combination of Promethazine and Levodopa.	Parkinsonism [8A00]	[62]
Pimavanserin	DMR7IVC	Moderate	Increased risk of prolong QT interval by the combination of Promethazine and Pimavanserin.	Parkinsonism [8A00]	[63]
Bromocriptine	DMVE3TK	Moderate	Additive CNS depression effects by the combination of Promethazine and Bromocriptine.	Parkinsonism [8A00]	[62]
Orphenadrine	DMW542E	Moderate	Additive anticholinergic effects by the combination of Promethazine and Orphenadrine.	Parkinsonism [8A00]	[17]
Methylscopolamine	DM5VWOB	Moderate	Additive anticholinergic effects by the combination of Promethazine and Methylscopolamine.	Peptic ulcer [DA61]	[17]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Promethazine and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[64]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Promethazine and Lefamulin.	Pneumonia [CA40]	[65]
Degarelix	DM3O8QY	Moderate	Increased risk of prolong QT interval by the combination of Promethazine and Degarelix.	Prostate cancer [2C82]	[21]
ABIRATERONE	DM8V75C	Moderate	Decreased metabolism of Promethazine caused by ABIRATERONE mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[66]
Enzalutamide	DMGL19D	Moderate	Increased risk of prolong QT interval by the combination of Promethazine and Enzalutamide.	Prostate cancer [2C82]	[21]
Relugolix	DMK7IWL	Moderate	Increased risk of prolong QT interval by the combination of Promethazine and Relugolix.	Prostate cancer [2C82]	[21]
Bicalutamide	DMZMSPF	Moderate	Increased risk of prolong QT interval by the combination of Promethazine and Bicalutamide.	Prostate cancer [2C82]	[21]
Terazosin	DM3JCVS	Moderate	Additive hypotensive effects by the combination of Promethazine and Terazosin.	Prostate hyperplasia [GA90]	[25]
Silodosin	DMJSBT6	Moderate	Additive hypotensive effects by the combination of Promethazine and Silodosin.	Prostate hyperplasia [GA90]	[25]
Levomepromazine	DMIKFEL	Moderate	Additive anticholinergic effects by the combination of Promethazine and Levomepromazine.	Psychotic disorder [6A20-6A25]	[17]
Neupro	DMHEAB1	Moderate	Additive hypotensive effects by the combination of Promethazine and Neupro.	Restless legs syndrome [7A80]	[62]
Quetiapine	DM1N62C	Moderate	Increased risk of prolong QT interval by the combination of Promethazine and Quetiapine.	Schizophrenia [6A20]	[20]
Aripiprazole	DM3NUMH	Moderate	Additive anticholinergic effects by the combination of Promethazine and Aripiprazole.	Schizophrenia [6A20]	[17]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Promethazine and Iloperidone.	Schizophrenia [6A20]	[20]
Paliperidone	DM7NPJS	Moderate	Increased risk of prolong QT interval by the combination of Promethazine and Paliperidone.	Schizophrenia [6A20]	[20]
Molindone	DMAH70G	Moderate	Additive anticholinergic effects by the combination of Promethazine and Molindone.	Schizophrenia [6A20]	[17]
Thiothixene	DMDINC4	Moderate	Additive anticholinergic effects by the combination of Promethazine and Thiothixene.	Schizophrenia [6A20]	[17]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Promethazine and Amisulpride.	Schizophrenia [6A20]	[67]
Asenapine	DMSQZE2	Moderate	Increased risk of prolong QT interval by the combination of Promethazine and Asenapine.	Schizophrenia [6A20]	[20]
Pimozide	DMW83TP	Major	Increased risk of prolong QT interval by the combination of Promethazine and Pimozide.	Schizophrenia [6A20]	[21]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Promethazine and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[20]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Promethazine and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[20]
Triptorelin	DMTK4LS	Moderate	Increased risk of prolong QT interval by the combination of Promethazine and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[21]
Pitolisant	DM8RFNJ	Moderate	Decreased metabolism of Promethazine caused by Pitolisant mediated inhibition of CYP450 enzyme.	Somnolence [MG42]	[21]
Telavancin	DM58VQX	Moderate	Increased risk of prolong QT interval by the combination of Promethazine and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[20]
Lenvatinib	DMB1IU4	Moderate	Increased risk of prolong QT interval by the combination of Promethazine and Lenvatinib.	Thyroid cancer [2D10]	[20]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Promethazine and Cabozantinib.	Thyroid cancer [2D10]	[21]
Papaverine	DMCA9QP	Moderate	Additive hypotensive effects by the combination of Promethazine and Papaverine.	Tonus and reflex abnormality [MB47]	[25]
Chlorpheniramine	DM5URA2	Moderate	Additive anticholinergic effects by the combination of Promethazine and Chlorpheniramine.	Vasomotor/allergic rhinitis [CA08]	[17]
Trimeprazine	DMEMV9D	Moderate	Additive anticholinergic effects by the combination of Promethazine and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[23]
Acrivastine	DMTIGA0	Moderate	Additive anticholinergic effects by the combination of Promethazine and Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[17]
Propafenone	DMPIBJK	Moderate	Increased risk of prolong QT interval by the combination of Promethazine and Propafenone.	Ventricular tachyarrhythmia [BC71]	[20]
Flecainide	DMSQDLE	Moderate	Increased risk of prolong QT interval by the combination of Promethazine and Flecainide.	Ventricular tachyarrhythmia [BC71]	[20]
Amiodarone	DMUTEX3	Major	Increased risk of prolong QT interval by the combination of Promethazine and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[20]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
D&C red no. 27	E00381	83511	Colorant
D&C red no. 30	E00456	3000709	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Hydrazine yellow	E00409	164825	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Brushite	E00392	104805	Diluent
Calcium hydrogenphosphate	E00294	24441	Diluent
Edetate disodium	E00186	8759	Complexing agent
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Promethazine 50 mg tablet	50 mg	Oral Tablet	Oral
Promethazine 25 mg tablet	25 mg	Oral Tablet	Oral
Promethazine 12.5 mg tablet	12.5 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] Promethazine FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7282).
• [3] Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother. 2014 Aug;58(8):4885-93.
• [4] Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020 Mar;19(3):149-150.
• [5] BDDCS applied to over 900 drugs
• [6] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [7] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [8] Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79.
• [9] Akathisia with combined use of midodrine and promethazine. JAMA. 2006 May 3;295(17):2000-1. Letter
• [10] Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics. 2003 Oct;13(10):619-26.
• [11] AMPK activation induced by promethazine increases NOXA expression and Beclin-1 phosphorylation and drives autophagy-associated apoptosis in chronic myeloid leukemia. Chem Biol Interact. 2020 Jan 5;315:108888. doi: 10.1016/j.cbi.2019.108888. Epub 2019 Nov 2.
• [12] Cholinesterase inhibition by phenothiazine and nonphenothiazine antihistaminics: analysis of its postulated role in synergizing organophosphate toxicity. Toxicol Appl Pharmacol. 1975 Feb;31(2):179-90.
• [13] A Gene Expression Biomarker Predicts Heat Shock Factor 1 Activation in a Gene Expression Compendium. Chem Res Toxicol. 2021 Jul 19;34(7):1721-1737. doi: 10.1021/acs.chemrestox.0c00510. Epub 2021 Jun 25.
• [14] An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
• [15] Enhanced activation of human NK cells by drug-exposed hepatocytes. Arch Toxicol. 2020 Feb;94(2):439-448. doi: 10.1007/s00204-020-02668-8. Epub 2020 Feb 14.
• [16] Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
• [17] Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
• [18] Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985): 930-2. [PMID: 3929968]
• [19] Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
• [20] Canadian Pharmacists Association.
• [21] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [22] Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
• [23] Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
• [24] Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
• [25] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
• [26] Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
• [27] Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
• [28] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
• [29] Achor MB, Extein I "Diet aids, mania, and affective illness" Am J Psychiatry 138 (1981): 392. [PMID: 7468847]
• [30] Bock JL, Nelson JC, Gray S, Jatlow PI "Desipramine hydroxylation: variability and effect of antipsychotic drugs." Clin Pharmacol Ther 33 (1983): 322-8. [PMID: 6130865]
• [31] Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
• [32] Multum Information Services, Inc. Expert Review Panel.
• [33] Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [34] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
• [35] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
• [36] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
• [37] Cerner Multum, Inc. "Australian Product Information.".
• [38] Burke RE, Fahn S, Mayeux R, Weinberg H, Louis K, Willner JH "Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease." Neurology 31 (1981): 1022-5. [PMID: 6115336]
• [39] Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
• [40] Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
• [41] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
• [42] Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
• [43] Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
• [44] Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
• [45] Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals, Cambridge, MA.
• [46] Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
• [47] Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [48] Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [49] Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [50] Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
• [51] Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
• [52] Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
• [53] Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
• [54] Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
• [55] Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
• [56] Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
• [57] Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
• [58] Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
• [59] Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
• [60] Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
• [61] Lake CR "Manic psychosis after coffee and phenylpropanolamine." Biol Psychiatry 30 (1991): 401-4. [PMID: 1912131]
• [62] Mims RB, Scott CL, Modebe O, Bethune JE "Inhibition of L-dopa-induced growth hormone stimulation by pyridoxine and chlorpromazine." J Clin Endocrinol Metab 40 (1975): 256-9. [PMID: 1117978]
• [63] Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
• [64] Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
• [65] Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
• [66] Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
• [67] Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.